Posted by Michael Wonder on 12 Oct 2020
NICE proposes simplifying how medicines and medical devices are selected for evaluation
12 October 2020 - As part of the work underway to review the methods and processes NICE uses to develop guidance on medicines, medical devices and diagnostics, NICE has launched a public consultation on proposals for changing how it selects the topics it will develop guidance on.
The proposals clarify the criteria that would see a device or diagnostic selected for NICE guidance development. In particular, these include where the costs and impacts are expected to be significantly cost incurring or cost saving, or there is uncertainty about the likely cost or the impact it would have on the health care system.
For medicines, the proposals confirm the commitment in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access that NICE will appraise all new active substances and significant licence extensions for existing medicines, except where there is a clear rationale not to do so (for example, if the topic is a duplicate or has a significant overlap with an existing topic or policy arrangement).
